Settled
Do investigational compounds improve body weight & composition versus placebo?
Mostly studied in dyslipidaemia. Also asked against other treatments.
Not modeled yetTrial evidence exists, but no mechanistic model yetWithout a model there is no decisive experiment to propose. Help build it. →
Where the evidence stands
Very likely. So far, established.
NoUnsureYes
- Belief
- 1.00 (range 0.90–1.00)
- Trials for
- 9
- Trials against
- 0
- Inconclusive
- 2
Already under way
No registered trial that could settle this is recruiting or active.
The evidence so far
- Registered trials
- 84
- With posted results
- 20
- Published papers
- 3
Of 145 decided analyses: 104 favor investigational compounds, 35 find no difference, 6 favor the comparator.
Papers
- Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial.Trial report · 2026
- Efficacy and safety of Efsubaglutide Alfa in "overrun" patients in the SUPER2 trial: A post-hoc analysis for comprehensive evaluation.Trial report · 2025
- Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind placebo-controlled study.Trial report · 2009
Trials
- A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of Intravenous Bimagrumab, Alone or in Addition to Open Label Subcutaneous Semaglutide, to Investigate the Efficacy and Safety in Overweight or Obese Men and WomenNCT05616013 · 40 posted results
- A Phase IIb, Randomised, Parallel, Double-Blind Placebo-Controlled and Open-Label Active Comparator Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes MellitusNCT03235050 · 51 posted results
- A Phase II, Randomized, Parallel Group, Dose-finding Study of Subcutaneously Administered BI 456906 for 16 Weeks, Compared With Placebo and Open-label Semaglutide in Patients With Type 2 Diabetes Mellitus.NCT04153929 · 39 posted results
- A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo and Dulaglutide in Participants With Type 2 DiabetesNCT04867785 · 24 posted results
- A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo and Once-Weekly Dulaglutide in Participants With Type 2 Diabetes MellitusNCT05048719 · 20 posted results
- A Randomized, Double-blind Placebo-controlled and Open-label Active-controlled, Parallel-group, Multicenter, Dose-ranging Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese SubjectsNCT03486392 · 7 posted results
- A 26-Week Randomized, Double-blind, Placebo-controlled, Dose-ranging Phase 2 Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes MellitusNCT02973321 · 5 posted results
- A Double-blind [Sponsor Unblinded], Randomized, Placebo-controlled, Staggered-parallel Study to Investigate the Safety, Tolerability, and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 DiabetesNCT01725126 · 5 posted results